Headquartered in Milford, Massachusetts, PLC Systems Inc. is a medical device company focused on innovative technologies for the cardiac and vascular markets.
PLC’s lead product, RenalGuard®, significantly reduces the onset of Contrast-Induced Nephropathy (CIN) in at-risk patients undergoing certain cardiac and vascular imaging procedures. CIN is a form of acute kidney injury resulting from toxic contrast agents that occurs in 10% to 20% of at-risk patients. RenalGuard is CE-marked and is being sold in Euorope and certain countries around the world. Two investigator-sponsored European studies have demonstrated RenalGuard’s effectiveness at preventing CIN. The CIN-RG pivotal study is underway in the U.S. to support a planned Premarket Approval (PMA) filing with the U.S. Food and Drug Administration.
RenalGuard is a closed loop system designed to minimize the risk of over- or under-hydration while maintaining the high urine flows recommended for the prevention of CIN.
AL-EMARA is the Exclusive Agent for PLC in Middle East Countries.